HopeStage
Back to all studies
CompletedNCT00080314

Aripiprazole for depression in bipolarity type I

About this title

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

Read the official source — NCT00080314
Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Tuscaloosa and 27 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJanuary 2004
Recruitment status
Completed
Enrollment listed in the registry
400
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00080314
Official title
Show the full official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Tuscaloosa · Little Rock · San Diego

25 more locations
  • Sherman Oaks
  • Norwich
  • West Haven
  • Jacksonville
  • Maitland
  • Orlando
  • Honolulu
  • Chicago
  • Lake Charles
  • Rockville
  • Durham
  • Raleigh
  • Beachwood
  • Dayton
  • Oklahoma City
  • Portland
  • Media
  • Memphis
  • Austin
  • Dallas
  • Houston
  • Lake Jackson
  • Wichita Falls
  • Arlington
  • Bellevue

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole and Placebo.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies